InvestSMART

Biome Australia Limited (ASX:BIO)

ALERT: Price-sensitive ASX Announcement for BIO
Current share price for BIO : $0.260 -0.135 (-34.18%)+
Announcement
Release
15 Dec 2025 8:23AM
Price at Release
$0.395
Full Release
download
Summary
Biome Australia Limited has announced the initiation of its first human clinical trial on the proprietary probiotic strain, Lactobacillus plantarum BMB18 (BMB18). This trial, which has received ethics approval and is registered with the Australia New Zealand Clinical Trials Registry, aims to evaluate the efficacy of BMB18 in patients with digestive symptoms such as bloating and discomfort, as well as sleep or mood disturbances. The study, set to begin in February 2026, will involve a randomized, double-blind, placebo-controlled approach with 240 participants. This research follows promising in vitro studies showing BMB18's potential in modulating immune responses, reducing oxidative stress, and maintaining intestinal barrier integrity. This trial is a crucial part of Biome’s Vision 27 strategic plan and is expected to enhance the company's competitive edge and expand its product offerings significantly in the gut health category.
Key Points
  • Biome's first human clinical trial for Lactobacillus plantarum BMB18 is initiated.
  • Trial registered with ANZCTR, scheduled for February 2026.
  • Involves 240 participants to assess efficacy for digestive and mood-related symptoms.
  • Follows successful in vitro tests showing immune modulation and stress reduction.
  • Part of Vision 27 strategy to strengthen Biome's market position and product range.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.